Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hal W Hirte. (2013) Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. OncoTargets and Therapy 6, pages 427-435.
Read now
Read now
Jianying Dong, Arlene Sereno, Dikran Aivazian, Emma Langley, Brian R. Miller, William B Snyder, Eric Chan, Matt Cantele, Ronald Morena, Ingrid B.J.K. Joseph, Antonio Boccia, Cyrus Virata, James Gamez, Grace Yco, Michael Favis, Xiufeng Wu, Christilyn P. Graff, Qin Wang, Ellen Rohde, Rachel Rennard, Lisa Berquist, Flora Huang, Ying Zhang, Sharon X. Gao, Steffan N. Ho, Stephen J. Demarest, Mitchell E. Reff, Kandasamy Hariharan & Scott M. Glaser. (2011) A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. mAbs 3:3, pages 273-288.
Read now
Read now
Articles from other publishers (29)
Aref Zayed, Jomana Al Hroot, Abdulraouf Mayyas & Belal Al‐Husein. (2023) Rapid high performance liquid chromatography method for erlotinib quantification in vitro: Application to study the effect of resveratrol on metabolism and cellular uptake of erlotinib. Fundamental & Clinical Pharmacology.
Crossref
Crossref
Lamya H. Al-Wahaibi, Essmat M. El-Sheref, Mohamed M. Hammouda & Bahaa G. M. Youssif. (2023) One-Pot Synthesis of 1-Thia-4-azaspiro[4.4/5]alkan-3-ones via Schiff Base: Design, Synthesis, and Apoptotic Antiproliferative Properties of Dual EGFR/BRAFV600E Inhibitors. Pharmaceuticals 16:3, pages 467.
Crossref
Crossref
Christos Damaskos, Nikolaos Garmpis, Dimitrios Dimitroulis, Anna Garmpi, Iason Psilopatis, Panagiotis Sarantis, Evangelos Koustas, Prodromos Kanavidis, Dionysios Prevezanos, Gregory Kouraklis, Michail V. Karamouzis, Georgios Marinos, Konstantinos Kontzoglou & Efstathios A. Antoniou. (2022) Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review. International Journal of Molecular Sciences 23:22, pages 14117.
Crossref
Crossref
Natalie Carroll, Reneau Youngblood, Alena Smith, Ana-Maria Dragoi, Brian A. Salvatore & Elahe Mahdavian. (2022) TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors. Biomedicines 10:11, pages 2906.
Crossref
Crossref
Monica A. Kamal, Yasmine M. Mandour, Mostafa K. Abd El-Aziz, Ulrike Stein & Hend M. El Tayebi. (2022) Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges. Molecules 27:17, pages 5537.
Crossref
Crossref
Evelina Cardoso, Monia Guidi, Nihel Khoudour, Pascaline Boudou-Rouquette, Elizabeth Fabre, Camille Tlemsani, Jennifer Arrondeau, François Goldwasser, Michel Vidal, Marie Paule Schneider, Anna Dorothea Wagner, Nicolas Widmer, Benoit Blanchet & Chantal Csajka. (2020) Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. Clinical Therapeutics 42:7, pages 1302-1316.
Crossref
Crossref
Mohammed A.I. Elbastawesy, Mohamed Ramadan, Yaseen A.M.M. El-Shaier, Ashraf A. Aly & Gamal El-Din A. Abuo-Rahma. (2020) Arylidenes of Quinolin-2-one scaffold as Erlotinib analogues with activities against leukemia through inhibition of EGFR TK/ STAT-3 pathways. Bioorganic Chemistry 96, pages 103628.
Crossref
Crossref
Yaping Lv, Wei Cang, Quanfu Li, Xiaodong Liao, Mengna Zhan, Huayun Deng, Shengze Li, Wei Jin, Zhi Pang, Xingdi Qiu, Kewen Zhao, Guoqiang Chen, Lihua Qiu & Lei Huang. (2019) Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer. Oncogenesis 8:12.
Crossref
Crossref
Mohammed A.I. Elbastawesy, Ashraf A. Aly, Mohamed Ramadan, Yaseen A.M.M. Elshaier, Bahaa G.M. Youssif, Alan B. Brown & Gamal El-Din A Abuo-Rahma. (2019) Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors. Bioorganic Chemistry 90, pages 103045.
Crossref
Crossref
Tae Kim, Soyoung Shin, Sarah Kim, Jürgen Bulitta, Kwon-Yeon Weon, Sang Joo, Eunsook Ma, Sun Yoo, Gi-Young Park, Dong Kwon, Seok Jeong, Da Lee & Beom Shin. (2017) Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. Molecules 22:9, pages 1515.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
495
547
.
Kelvin KW Chan, Anne-Marie Glenny, Jo C Weldon, Susan Furness, Helen V Worthington & Helen Wakeford. (2015) Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. Cochrane Database of Systematic Reviews 2015:12.
Crossref
Crossref
Andrew X. ZhuOlivier RosmorducT.R. Jeffry EvansPaul J. RossArmando SantoroFlair Jose CarrilhoJordi BruixShukui QinPaul J. ThuluvathJosep M. LlovetMarie-Aude LeberreMarkus JensenGerold MeinhardtYoon-Koo Kang. (2015) SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology 33:6, pages 559-566.
Crossref
Crossref
Djoeke de Wit, Henk-Jan Guchelaar, Jan den Hartigh, Hans Gelderblom & Nielka P. van Erp. (2015) Individualized dosing of tyrosine kinase inhibitors: are we there yet?. Drug Discovery Today 20:1, pages 18-36.
Crossref
Crossref
Yin-dong Song, Ke-fei Zhang, Dong Liu, Yan-qi Guo, Da-yong Wang, Ming-yu Cui, Gang Li, Yuan-xin Sun, Jian-hui Shen, Xin-gang Li, Long Zhang & Feng-jun Shi. (2014) Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin. Tumor Biology 35:7, pages 7017-7024.
Crossref
Crossref
Roshan Karki, Brandon-Luke L. Seagle, Wilberto Nieves-Neira & Shohreh Shahabi. (2014) Taxanes in combination with biologic agents for ovarian and breast cancers. Anti-Cancer Drugs 25:5, pages 536-554.
Crossref
Crossref
Susan A. KrikorianKanza Shamim. (2012) Adherence Issues for Oral Antineoplastics. American Journal of Lifestyle Medicine 7:3, pages 206-222.
Crossref
Crossref
Sharon L. Longo, David J. Padalino, Sandra McGillis, Kirstin Petersen, Hartmut Schirok, Oliver Politz, Gregory W. Canute & Dawn E. Post. (2011) Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Investigational New Drugs 30:6, pages 2161-2172.
Crossref
Crossref
Shinji Kuroda, Tomohisa Yokoyama, Justina Tam, Ailing Scott, Li Ma, Manish Shanker, Jiankang Jin, Corbin Goerlich, David Willcutts, Jack Roth, Konstantin Sokolov, Keith Johnston & Rajagopal Ramesha. 2012. Pulmonary Nanomedicine. Pulmonary Nanomedicine
15
44
.
Olli Lohi, Martine Vornanen, Marketta Kähkönen, Kim Vettenranta, Katriina Parto & Mikko Arola. (2012) Recurrent Congenital Fibrosarcoma With Heart Metastases. Journal of Pediatric Hematology/Oncology 34:5, pages e202-e205.
Crossref
Crossref
Peter Mazzone & Tarek Mekhail. (2012) Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine 106:4, pages 473-492.
Crossref
Crossref
Joseph P. Garay & Joe W. Gray. (2012) Omics and therapy - A basis for precision medicine. Molecular Oncology 6:2, pages 128-139.
Crossref
Crossref
Lisa Nolan Wright, Andrew Ryscavage, Glenn Merlino & Stuart H. Yuspa. (2012) Modeling the Transcriptional Consequences of Epidermal Growth Factor Receptor Ablation in Ras-Initiated Squamous Cancer. Clinical Cancer Research 18:1, pages 170-183.
Crossref
Crossref
Ioannis N Melas, Alexander Mitsos, Dimitris E Messinis, Thomas S Weiss & Leonidas G Alexopoulos. (2011) Combined logical and data-driven models for linking signalling pathways to cellular response. BMC Systems Biology 5:1.
Crossref
Crossref
Craig D. Woodworth, Laura P. Diefendorf, David F. Jette, Abdulmajid Mohammed, Michael A. Moses, Sylvia A. Searleman, Dan A. Stevens, Katelynn M. Wilton & Sumona Mondal. (2011) Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16. Virology 421:1, pages 19-27.
Crossref
Crossref
Mi-Sook Kim. (2011) Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. Biomolecules and Therapeutics 19:4, pages 371-389.
Crossref
Crossref
Xudong Luan, Chunmei Gao, Nannan Zhang, Yuzong Chen, Qinsheng Sun, Chunyan Tan, Hongxia Liu, Yibao Jin & Yuyang Jiang. (2011) Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors. Bioorganic & Medicinal Chemistry 19:11, pages 3312-3319.
Crossref
Crossref
Gregory E Holt, Eckhard R Podack & Luis E Raez. (2011) Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 8:1, pages 43-54.
Crossref
Crossref
Anthony B Daniels, Matt L Miller, Amy Kotecha & David H Abramson. (2010) UVEAL METASTASIS FROM NONSMALL CELL LUNG CARCINOMA WITH DRAMATIC RESPONSE TO ERLOTINIB. RETINAL Cases & Brief Reports 4:4, pages 390-393.
Crossref
Crossref